Login to Your Account

Pharmion Files NDA On Vidaza For Myelodysplastic Syndromes

By Kim Coghill

Tuesday, December 30, 2003
Pharmion Corp. filed a new drug application seeking approval to market Vidaza, an orphan-designated product, as a treatment for myelodysplastic syndromes. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription